Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520517 · ClinicalTrials.gov registry record · Phase 1
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
A Phase 1 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03520517 is a Phase 1 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT03520517, a Phase 1 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Phase 1, open-label study of BHV-0223 in ALS.
Interventions
- DRUG BHV-0223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520517
The ClinicalTrials.gov registry entry for NCT03520517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BHV-0223 is the first listed.
NCT03520517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520517 about?
NCT03520517 is a clinical study titled "Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS". Phase 1, open-label study of BHV-0223 in ALS.
What is the current status of trial NCT03520517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-02-02. Estimated completion is 2018-10-08.
What interventions are being tested in trial NCT03520517?
The interventions under investigation include: BHV-0223 (DRUG).
Who is sponsoring clinical trial NCT03520517?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.